source
- Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80%A new analysis warns that confidential agreements between the Trump administration and more than two dozen drug makers could dramatically shrink the savings expected from the "most‑favored‑nation"…
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…